Drug intelligence / Profile preview

yiganling

Development stage
Unknown
Lead developer
Yantai Dongcheng Biochemicals
Modality
Small Molecules
Administration
Oral
01

Overview

Yiganling Drop Pills (益肝灵滴丸) is a hepatoprotective pharmaceutical product developed and manufactured by Nanchang Hongyi Pharmaceutical. The active ingredient is silymarin, a mixture of flavonolignans extracted from the seeds of the milk thistle plant (*Silybum marianum*). The drug is approved in China for the treatment of chronic hepatitis and persistent hepatitis. It functions by stabilizing liver cell membranes, preventing the entry of toxins, and stimulating nucleolar RNA polymerase I, which enhances ribosomal protein synthesis and promotes the regeneration of hepatocytes. Additionally, it exhibits potent antioxidant properties, scavenging reactive oxygen species and inhibiting lipid peroxidation to protect liver tissue from oxidative stress. The drop pill formulation is designed to enhance the solubility and bioavailability of the lipophilic silymarin complex.

Brand names
Yiganling Drop Pills
Other names
益肝灵滴丸Silymarin Drop Pillsyiganling
02

Targets

Pol I (RNA polymerase I)

Beyond the preview

Go deeper on yiganling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on yiganling.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call